2237P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial

Huyghe, Nicolas;Benidovskaya, Elena;Masoodi, Tariq;Carrasco, Javier;Van den Eynde, Marc;et.al.
(2023) ESMO Congress 2023 — Location: (Spain) Madrid (20.October.2023)

Files

2023_Huyghe_ESMO_2237P.pdf
  • Open Access
  • Adobe PDF
  • 89.69 KB
Download

Details

Authors
Show more
Abstract
BACKGROUND : This trial explores the clinical efficacy and safety of AVE, CET and IRI for treatment refractory MSS mCRC. We aim at characterizing the immune response for biomarker discovery through associated translational research. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Huyghe, N., Benidovskaya, E., Masoodi, T., Carrasco, J., De Cuyper, A., Sinapi, I., Vempalli, F., Verstraelen, E., Goffette, P., Ghaye, B., Papier, M., Bedognetti, D., van Maanen, A., Castella, M.-L., Galon, J., & Van den Eynde, M. (2023). 2237P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial. Annals of Oncology, 34(Suppl 1), S1152. https://doi.org/10.1016/j.annonc.2023.09.1265 (Original work published 2023)